PF-07304814 for Inpatients With COVID-19 (An ACTIV-3/​TICO Treatment Trial)

Grandits et al., NCT05780541, NCT05780541, Feb 2024
Mortality -22% improvement lower risk ← → higher risk Discharge 44% Lufotrelvir  Grandits et al.  LATE TREATMENT RCT Is late treatment with lufotrelvir beneficial for COVID-19? Double-blind RCT 58 patients in multiple countries Trial underpowered to detect differences c19early.org Grandits et al., NCT05780541, February 2024 0 0.5 1 1.5 2+ RR
RCT 58 patients showing no significant differences with lufotrelvir. This is a 2021 study which has not been published yet. Results were made available on clinicaltrials.gov in 2024.
Important missing comments or errors? Let us know.
risk of death, 21.9% higher, RR 1.22, p = 0.77, treatment 9 of 32 (28.1%), control 6 of 26 (23.1%), day 90.
risk of no hospital discharge, 43.8% lower, RR 0.56, p = 0.11, treatment 9 of 32 (28.1%), control 13 of 26 (50.0%), NNT 4.6, day 90.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Grandits et al., 9 Feb 2024, Double Blind Randomized Controlled Trial, placebo-controlled, multiple countries, peer-reviewed, 1 author, trial NCT05780541 (history).
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 200,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. IMA and WCH provide treatment protocols.
  or use drag and drop   
Submit    
Post
Share
@CovidAnalysis
FAQ
Public domain CC0 1.0